The lack of biomarkers of ICI in SCLC and the limitations of PD‐L1 immunohistochemical analysis indicate the importance and need for research to further evaluate uncharacterized biomarkers of ICI therapy in SCLC and their association with clinical outcomes. Here, CD274 is linked to small cell lung carcinoma.